Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Teva
Argus Health
QuintilesIMS
Chubb
Citi
McKesson
Baxter
Daiichi Sankyo
McKinsey

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,999,007

« Back to Dashboard

Which drugs does patent 7,999,007 protect, and when does it expire?

Patent 7,999,007 protects REMODULIN and is included in one NDA.

This patent has twelve patent family members in seven countries.
Summary for Patent: 7,999,007
Title:Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.
Inventor(s): Jeffs; Roger (Chapel Hill, NC), Zaccardelli; David (Cary, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:12/276,707
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Formulation;

Drugs Protected by US Patent 7,999,007

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-001 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-002 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-003 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-004 May 21, 2002 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,999,007

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,653,137 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same ➤ Subscribe
8,658,694 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same ➤ Subscribe
9,327,031 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,999,007

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 101827612 ➤ Subscribe
China 103181893 ➤ Subscribe
European Patent Office 2200650 ➤ Subscribe
European Patent Office 2711024 ➤ Subscribe
Spain 2562669 ➤ Subscribe
Japan 2010538092 ➤ Subscribe
Japan 2016047850 ➤ Subscribe
South Korea 20100074169 ➤ Subscribe
South Korea 101693049 ➤ Subscribe
Japan 2013241468 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Moodys
Citi
Deloitte
Argus Health
Daiichi Sankyo
Queensland Health
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot